These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36870799)

  • 21. Medical device regulation for manufacturers.
    McAllister P; Jeswiet J
    Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Regulatory Framework for Medical Devices in Japan: Current Regulatory Considerations Regarding Clinical Studies.
    Konishi A; Isobe S; Sato D
    J Vasc Interv Radiol; 2018 May; 29(5):657-660. PubMed ID: 29548874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative.
    Warner JJ; Crook HL; Whelan KM; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; Hernandez AF; McClellan MB; Califf RM; Brown N;
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006606. PubMed ID: 32683985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
    Desai KG; Obayashi H; Colandene JD; Nesta DP
    J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
    Azuma K; Yamanaka S
    Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparative Study of Medical Device Regulations:: US, Europe, Canada, and Taiwan.
    Chen YJ; Chiou CM; Huang YW; Tu PW; Lee YC; Chien CH
    Ther Innov Regul Sci; 2018 Jan; 52(1):62-69. PubMed ID: 29714608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
    Tajima G; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International regulatory aspects of clinical periodontal research.
    Cooley WE; Castellion AW
    Ann Periodontol; 1997 Mar; 2(1):18-30. PubMed ID: 9151540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory approval of peripheral endovascular revascularization devices in the United States: is the horse still in the barn?
    Weinberger J; Rundback JH; Ratchford EV
    Am J Ther; 2005; 12(2):186-91. PubMed ID: 15767839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan.
    Carolina IL; Antònia A; Mercè O; Antonio V
    Expert Opin Biol Ther; 2022 Jul; 22(7):831-842. PubMed ID: 35762253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is involved in a regulatory trial investigating a new medical device?
    McKay PJ; Resendes S; Schemitsch E; Bhandari M
    J Long Term Eff Med Implants; 2007; 17(2):165-71. PubMed ID: 18540859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
    Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
    Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.